Roivant Sciences Ltd (NASDAQ:ROIV) shares traded 6.40% higher at $11.30 on Wall Street last session.
ROIV stock price is now 6.56% away from the 50-day moving average and 0.27% away from the 200-day moving average. The market capitalization of the company currently stands at $8.06B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 100,000 shares of the company’s stock on May 20 ’25. The stock was sold for $1,095,000 at an average price of $10.95. Upon completion of the transaction, the President & COO now directly owns 1,077,197 shares in the company, valued at $12.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’25, Officer Venker Eric bought 100,000 shares of the business’s stock. A total of $1,094,986 was incurred on buying the stock at an average price of $10.95. A total of 38.56% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $8.73 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 37.91, and a quick ratio of 37.91.
The net profit margin was -225.71% and return on equity was -8.17% for ROIV. The company reported revenue of $9.02 million for the quarter, compared to $15.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.05 percent. For the current quarter, analysts expect ROIV to generate $7M in revenue.